Japan Market Approval On Track For All-Case Surveillance Drugs From Lilly, GSK, Otsuka
This article was originally published in PharmAsia News
TOKYO - A string of drugs are on track for marketing approval in Japan, as the pharmaceutical subcommittee of the Pharmaceutical Affairs and Food Sanitation Council confirmed its consent for approval of 22 new drugs and additional indications
You may also be interested in...
UK's cost effectiveness watchdog is uncertain about Revolade's long-term effects and cost
Japan's Ministry of Health, Labor and Welfare has recommended 10 drugs for marketing approval; these include new drugs from Johnson & Johnson, Eli Lilly, GlaxoSmithKline and Nippon Medi-Physics
Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.